The vintage image of FDA items is courtesy of Hillerman Film and Google Images.

Health Friday is a series devoted to information about Big Pharma, vaccines, general health, and associated topics. There are Important Notifications by our host, Wolf Moon; the Rules of our late, good Wheatie; and, certain caveats from Yours Truly, of which readers should be aware. They are linked here. Note: AI-generated items in today’s offering will be cited as such. If readers, wish to post AI-generated items in today’s discussion thread, they must cite their source. Thank you.

Betrayal by the FDA?

Yours Truly begins here: https://www.thekingstonreport.com/p/fda-drops-placebo-controlled-trial, “FDA Drops Placebo-Controlled Trial Requirement for NEW mRNA Vaccines”, Karen Kingston, 28 May 2026. Please see the screenshot from this article, below:

The “vaccine” that the FDA will meeting about regarding review of the BLA application from Moderna of, is none other than mRNA-1010, the company’s modRNA influenza “vaccine” that is other component of the company’s “holy grail vaccine” — mRNA-1083 (mCOMBRIAX.) mCOMBRIAX is a “combo-vaccine” of mRNA-1010 plus mRNA-1283 (mNEXSPIKE, Moderna’s modRNA “lite” COVID-19 bioweapon “vaccine.) . mCOMBRIAX is already approved for use in the European Union. Yours Truly exposed the situation regarding mRNA-1083 (mCOMBRIAX), and the maneuvering by Moderna to get the product FDA-approved for use in the United States: first, mRNA-1010 (mCOMBRIAX): https://www.theqtree.com/2026/02/27/health-friday-2-27-2026-open-thread-modernas-mrna-1010-and-the-end-run-around-hhs-secretary-kennedy-jr-part-one/; https://www.theqtree.com/2026/03/06/health-friday-3-6-2026-open-thread-modernas-mrna-1010-and-the-end-run-around-hhs-secretary-keenedy-jr-part-two/. Second, Yours Truly exposed mNEXSPIKE (mRNA-1283; the other component of mRNA-1083, mCOMBRIAX): https://www.theqtree.com/2026/03/13/health-friday-3-13-2026-open-thread-meet-modernas-mrna-1283-mnexspike-the-other-component-of-mrna-1083-mcombriax-part-one/; https://www.theqtree.com/2026/03/20/health-friday-3-20-2026-open-thread-meet-modernas-mrna-1283-mnexspike-the-other-component-of-mrna-1083-mcombriax-part-two/. The “TD;LR” of the above links this screenshot from this source (the European Medicines Agency Assessment and Recommendation report on mCOMBRIAX, found here: https://www.ema.europa.eu/en/documents/assessment-report/mcombriax-epar-public-assessment-report_en.pdf, 26 February 2026):

The “TD;LR” summary of the mRNA-1010 situation in the United States: Moderna is desperate to get FDA approval for this modRNA “influenza vaccine”, so the company can proceed to finish getting mCOMBRIAX also FDA-approved. The backstory on this situation is outlined here: https://www.patsnap.com/resources/blog/articles/pfizer-vs-moderna-mrna-patent-strategies-and-pipelines/, updated 2 April 2026. A screenshot from this article is below:

However, Moderna has ALREADY applied for a Patent for mRNA-1010: https://patents.google.com/patent/EP4274607A1/en; title: “Seasonal rna influenza virus vaccines.” The Patent application was submitted on 10 January 2022. The current Status of the application is “Pending.” By the way, the Patent claims state that as many as SEVEN different types of influenza virus strains can be used in the formulation of mRNA-1010. Also notice that the Patent application was filed back in January 2022: this means that the laboratory work to perform the experiments, aggregate data, analyze the data, and so on, was begun years before the application submission.

However, Moderna has ALREADY applied for a Trade Mark (TM) for mRNA-1010, under the brand name mFLUSIVA. The application was submitted on 27 February 2026: https://uspto.report/TM/99674080. **** It was on 26 February 2026 that the European Medicines Agency (cited above) recommended the use of mCOMBRIAX (mFLUSIVA + mNEXSPIKE combination “vaccine”) in the European Union.

The VRBPAC panel of the FDA will meet on 18 June 2026 to consider the use of mRNA-1010 (mFLUSIVA) in the United States: https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-18-2026-meeting-announcement. The current member roster of the VRBPAC panel is listed here: https://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-committee; current roster as of 19 May 2026. The Chair position is “Vacant.” This meeting appears to be the “meeting with outside experts” that the Kingston Report is referring to (cited above.)

It appears that, in Yours Truly’s opinion, Moderna is performing “all the right moves” in order to ensure that mRNA-1010 (mFLUSIVA) is approved by the FDA for use in the United States as soon as possible. This includes, apparently, maneuvering to have Dr. Vinay Prasad (who refused the BLA application for mRNA-1010 in February 2026) removed from his position at the FDA. Per the Kingston Report, cited above:

This “FDA meeting with Moderna” was the “Type A” meeting that Yours Truly wrote about in the Health Friday posts cited above.

Does the reader see how the game is played by Big Pharma? It appears that Moderna will not allow anyone to interfere with the company’s goal of getting mRNA-1010 (mFLUSIVA) through the FDA approval process and have the injectable ready for the United States 2026-2027 “flu season market”; and, also, that Moderna will not allow anyone to interfere with the company’s goal of getting mRNA-1083 (mCOMBRIAX) through the FDA approval process and have the injectable ready for the United States market as soon as possible.

Peace, Good Energy, Respect: PAVACA

(Intellectual Property Disclaimer and Notice: Except for linked URLs and other items in today’s offering that are available on the Internet, the ideas and/or opinions of today’s offering are by PAVACA. Credit must be given to PAVACA if the ideas and/or opinions of today’s offering are used by other blog writers; by podcasters; or in print or social media.)